KTP Associate Conference 2019 (20-21 June | Belfast, UK) Dr Abdo Alnabulsi, KTP Associate Vertebrate Antibodies Ltd-University of Aberdeen, attended the KTP Associate Conference in Belfast, UK. Abdo Alnabulsi gave a presentation entitled: The Development of Antibodies and Characterisation of Novel Prognostic Biomarkers in Colorectal Cancer. [...]
March 2019- Joining forces with Forsage Holdings Ltd VERTEBRATE ANTIBODIES LTD (VAL) is delighted to announce a Strategic Alliance with Forsage Holdings Ltd (FH) Forsage Holdings Ltd is a dynamic and growth focused Irish family owned private Investment Company with investments in established and fast evolving [...]
Animal Pharm: The Vertebrate Antibodies and Marinnovac Collaboration The new firm is based in O Porriño, Spain. It is aiming to fast-track fish and shrimp disease prevention strategies through collaborations. The firm's focus is on autogenous, experimental and licensed vaccines, as well as diagnostic services. The [...]
A Timeline of Our Grants and Announcements May 2017 - ISCF Agri-food technology catalyst seeding catalyst award Vertebrate Antibodies in collaboration with Professor Sam Martin at Aberdeen University have secured a BBSRC SEEDING CATALYST AWARD to support a project on developing [...]
Vertebrate Antibodies - Publications Alnabulsi A, Cash B, Hu Y, Silina L, Alnabulsi A, Murray GI (2019). The expression of brown fat associated proteins in colorectal cancer and the relationship of uncoupling protein 1 with prognosis. Int J Cancer. PMID: 30737786. DOI: 10.1002/ijc.32198. Veenstra KA, Alnabulsi [...]
Vertebrate Antibodies Ltd has become a member of the Pivotal Scientific Limited (PSL) Alliance. PSL Alliance is created to facilitate the growth of members’ sales and improve their brand awareness (http://www.pivotalscientific.com/psl-alliance).
VAL products catalogue has passed the 150 mark. The antibodies are towards key targets within a wide range of organisms for research and clinical applications, all of which are currently available for licensing from Cancer Research Technology at their Ximbio site (https://ximbio.com/organisation/48/vertebrate-antibodies-limited).
March 2016 – Development of monoclonal antibodies to monitor animal’s health as part of European project
VetBioNet is a European project funded under a call from Horizon 2020 for funding large research infrastructures. VetBioNet (http://www.vetbionet.eu/) overarching goal is to establish and maintain a comprehensive network of pre-eminent high-containment (BSL3) research facilities, academic institutes, international organisations and industry partners that is dedicated to advance research [...]
April 2015 – Development of monoclonal antibodies for parasite-specific molecules In April 2015 a European Union Horizon 2020 Project funded to support the prospective fish-farming industry has started. ParaFishControl (www.parafishcontrol.eu) overarching goal is to increase the sustainability and competitiveness of the European aquaculture industry by improving our understanding [...]
VAL new antibodies towards key zebrafish targets: The antibodies are specific to zebrafish targets involved in key biological pathways including immunity, angiogenesis, tumour suppressors and drug metabolisers. The list are as follows; CD4, FOXP3, IFNγ(1), p53, MMP9, AKT1, FLT1, FGF1, TIMP2a, PXR and CYP3C1. Datasheets available on the [...]